Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Global $200 Billion Opportunity for Nanoparticle Drug Delivery Market by 2024 - Size, Current Trends, and Dynamics

      Research and Markets Logo

      News provided by

      Research and Markets

      Apr 20, 2018, 11:00 ET

      Share this article

      Share this article


      DUBLIN, April 20, 2018 /PRNewswire/ --

      The "Global Nanoparticle Drug Delivery Market, Dosage, Price and Clinical Pipeline Outlook 2024" report has been added to ResearchAndMarkets.com's offering.

      The report estimates the global nanoparticle drug market to reach over US$ 200 Billion by 2024 at a CAGR of 10%.

      Growth promoting factors like increase in global prevalence of various clinical indications like cancer, diabetes and rheumatoid arthritis are bound to fuel the market growth with oncology being the dominant segment. The increasing demand for effective treatment methods to provide for the rising pool of patients are expected to help the segment retain dominance over the report's forecast period as well.

      The nanoparticles drug delivery market however faces some major challenges that are anticipated to hamper with its future growth. High demand of investments, scientific and technical limitations and overcrowding of vendors and marketing challenges such as exorbitant pricing of therapeutics, limited market penetration and low awareness are hurdles that need to be taken care of to enhance the potential of nanoparticle drug delivery segment.

      Advancement in nanotechnology has resulted in the entry of many types of nanoparticles in the market. Nanocrystal and liposomes are currently the most popular nanoparticles in use, followed by micelles and dendrimers. Nanocrystal, liposomal and micelle formulations of therapeutics are being developed and marketed which is bound to increase the market size in the future.

      Geographical analysis of the nanoparticle drug delivery method projects the increasing dominance of US with more than 40% of the global market, followed by Europe. However, the market size is anticipated to increase in the Asia Pacific and Latin American region during the forecast period due to multiple growth factors supporting the analysis, such as increase in patient base and the rising interest of key players like Johnson & Johnson and Novartis in the region.

      This research report on global nanoparticle drug delivery market provides an in-depth analysis of the market with special emphasis on the global market size, current market trends, dynamics and other factors that might have an impact on the market. Comparative price, dosage and therapy cost analysis of original drugs with nanoparticle formulations analyses the promising potential of Nanoparticle drug delivery, ultimately proving its superiority.

      Key Topics Covered

      1. Nanoparticles - Revolutionizing Drug Delivery Method
      1.1 Prologue to Targeted Drug Delivery by Nanoparticles
      1.2 Nanoparticle Drug Delivery -Enhancing the Efficacy of Therapeutics by Nanotechnology

      2. Need for Nanoparticle Drug Delivery
      2.1 Limitations of Traditional Drug Delivery Techniques
      2.2 Rising Demand for Better Targeted Drug Delivery Techniques in the Oncology Segment

      3. Superiority of Nanoparticle Based Drug Delivery over Traditional Drug Delivery
      3.1 Better Therapeutic Outcome than Conventional Drug Delivery Methods
      3.2 Role of Nanoparticles in Better Diagnosis of Cancer

      4. Importance of Nanoparticle Drug Delivery in Cancer Therapy
      4.1 Wide Application of Nanoparticles in Cancer Therapy
      4.2 Mechanisms of Nanoparticle Internalization in Cancer Cells for Imaging & Therapy

      5. Existing Techniques For Nanoparticle Drug Delivery
      5.1 Nanocrystals
      5.2 Liposomes
      5.3 Dendrimers
      5.4 Micelle Based Drug Delivery

      6. Upcoming Nanoparticle Drug Delivery Techniques
      6.1 Polymeric Nanoparticles
      6.2 Metal based Nanoparticles (Gold, iron oxide)
      6.3 Fullerenes & Carbon Nanotube
      6.4 Quantum Dots Delivery

      7. Global Nanoparticle Drug Market Overview
      7.1 Current Market Scenario
      7.2 Global Nanoparticle Drug Clinical Pipeline Overview

      8. Price & Dosage Analysis of Commercially Available Nanoparticle Therapeutics
      8.1 Liposomal Doxorubicin
      8.1.1 Availability, Price & Mechanism of Action
      8.1.2 Dosage in Various Clinical Indications
      8.1.3 Liposomal Doxorubicin (Nanoparticle) v/s Traditional Doxorubicin - Comparative Analysis
      8.2 Amphotericin
      8.2.1 Availability, Price & Mechanism of Action
      8.2.2 Dosage by Indication
      8.2.3 Comparative Analysis- Conventional Amphotericin B v/s Nanoparticle Formulations
      8.3 Paclitaxel (Taxol, Onxal)
      8.3.1 Availability,Price & Mechanism of Action
      8.3.2 Dosage Analysis in Various Types of Cancer
      8.3.3 Paclitaxel v/s Abraxane(liposomal)
      8.4 Sirolimus (Rapamune)
      8.4.1 Availability,Price & Mechanism of Action
      8.4.2 Rapamune - Dosage Analysis
      8.5 Emend (Aprepitant Nanocrystal)
      8.5.1 Availability & Price
      8.5.2 Dosage Analysis
      8.6 Megace ES (Enhanced Stability)
      8.6.1 Availability, Price & Mechanism of Action
      8.6.2 Comparative Dosage Analyis - Megace v/s Megace ES
      8.7 Estradiol Topical Emulsion(Estrasorb)
      8.8 Other Nanoparticle Therapeutic Formulations
      8.8.1 Feraheme
      8.8.2 Triglide - Nanocrystal Version of Tricor

      9. Nanoparticle Drug Delivery - Market Trend & Patent Distribution Analysis
      9.1 Patent Filing Status in Nanoparticle Drug Delivery
      9.2 Patent Distribution by Nanomaterial Type
      9.3 Patent Distribution by Stimulus
      9.4 Patent Distribution by Route of Administration & Forms of Drug Delivery

      10. Driving Factors of Nanoparticle Drug Delivery Market
      10.1 Increasing Prevalence of Disease & the Need for Better Therapeutics
      10.2 Better Reliability & Safety than Conventional Therapeutics
      10.3 Advancement in Research & Development
      10.4 Promising Investment & Market Potential
      10.5 Rapid Advancement in Innovative and Superior Technology

      11. Challenging Aspects of Nanoparticle Drug Delivery Segment
      11.1 Highly Expensive Technique & Nanoparticle Products
      11.2 Scientific & Technical Limitation Related to Nanoparticles Drug Delivery
      11.3 Regional Limitation & Low Market Penetrance
      11.4 Dominance of Conventional Drug Delivery Segment

      12. Future Forecast & Market Analysis of Global Nanoparticle Drug Delivery Market

      13. Global Nanoparticle Drug Clinical Pipeline by Company, Indication & Phase
      13.1 Unknown
      13.2 Research
      13.3 Preclinical
      13.4 Clinical
      13.5 Phase-I
      13.6 Phase-I/II
      13.7 Phase-II
      13.8 Phase-II/III
      13.9 Phase-III
      13.10 Preregistration
      13.11 Registered

      14. Marketed Nanoparticle Drug Clinical Insight by Company & Indication
      14.1 Rilpivirine (Edurant)
      14.2 Albumin-Bound Paclitaxel (Abraxane, Coraxane & Coroxane)
      14.3 Meloxicam (VIVLODEX)
      14.4 Ferumoxytol (Feraheme & Rienso)
      14.5 Paclitaxel Liposomal - Sun Pharma Advanced Research Company
      14.6 Fenofibrate (Lipanthyl & TriCor)
      14.7 Doxorubicin Liposomal (Caelyx & Doxil)
      14.8 Vincristine Liposomal (Marqibo)
      14.9 Fenofibrate (Triglide)
      14.10 Rexin-G
      14.11 Estradiol Topical (Estrasorb)
      14.12 Glycyrrhiza/Phosphatidylcholine (Phosphogliv)
      14.13 Paclitaxel Nanoparticle (Nanoxel)

      15. Competitive Landscape
      15.1 Abraxis BioScience
      15.2 Access Pharmaceuticals
      15.3 Alnylam Pharmaceuticals
      15.4 Amgen
      15.5 Arrowhead Research
      15.6 BIND Therapeutics
      15.7 Cadila Healthcare
      15.8 Celegen Corporation
      15.9 Celsion Corporation
      15.10 Genzyme Corporation
      15.11 Merck
      15.12 NanoCarrier
      15.13 Nippon Kayaku
      15.14 Nanobiotix
      15.15 Novavax
      15.16 Pfizer
      15.17 Roche
      15.18 Samyang
      15.19 Sanofi
      15.20 Takeda Pharmaceutical

      For more information about this report visit https://www.researchandmarkets.com/research/kn78v5/global_200?w=5

      Media Contact:

      Research and Markets
      Laura Wood, Senior Manager
      [email protected]

      For E.S.T Office Hours Call +1-917-300-0470
      For U.S./CAN Toll Free Call +1-800-526-8630
      For GMT Office Hours Call +353-1-416-8900

      U.S. Fax: 646-607-1907
      Fax (outside U.S.): +353-1-481-1716

      SOURCE Research and Markets

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.